Stop TB Partnership

Wave 9 Application Resources

Below is a list of resources which can be used when you are developing your proposal:

• Wave 9 grants framework and timeline
• Technical brief and useful documents
  
  
  • Wave 9 technical brief on drug-resistant tuberculosis
  • Budget instructions
  • Eligibility requirements
  • Frequently Asked Questions (FAQs)
  • Stop TB’s Language Guide - United to End TB: Every Word Counts
  • Sample application for viewing only
  • Application in French and Russian

Resources on drug-resistant tuberculosis

USAID global accelerator to End TB

Delivering comprehensive supportive care to people with drug-resistant tuberculosis

Best practices in engagement of all health care providers in the management of drug resistant tuberculosis

Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis

Stop TB Partnership field guide: the role of laboratory systems in TB case detection

Active tuberculosis drug-safety monitoring and management (aDSM): Framework for implementation

Moore BK, Erasmus L, Ershova J, Smith SE, Ndjeka N, Podewils LJ (2020) Pre-treatment loss to follow-up among children with multidrug-resistant tuberculosis in South Africa, 2008–2010. PLoS ONE 15(4): e0230504.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0230504

Cox H, Dickson-Hall L, Ndjeka N, van’t Hoog A, Grant A, Cobelens F, et al. (2017) Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study. PLoS Med 14(2): e1002238.
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002238

Project description of PATH’s digital system supports adherence to TB treatment in Viet Nam: Using mHealth to combat multidrug-resistant tuberculosis across Vietnam

Munsiff SS, Ahuja SD, Li J, Driver CR. Public–private collaboration for multidrug-resistant tuberculosis control in New York City. Int J Tuberc Lung Dis. 2006;10(6):639–48.
https://www.ingentaconnect.com/content/iuatld/ijtld/2006/00000010/00000006/art00009

Sachdeva KS, Raizada N, Sreenivas A, van't Hoog AH, van den Hof S, Dewan PK, et al. (2015) Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India. PLoS ONE 10(5): e0126065.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0126065

Peter J Dodd, Charalambos Sismanidis, James A Seddon. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. The Lancet Infectious Diseases, Volume 16, Issue 10
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30132-3/fulltext

Tupasi, T.E., Garfin, A.M.C.G., Kurbatova, E.V., Mangan, J.M., Orillaza-Chi, R., Naval, L.C., Balane, G.I., Basilio, R., Golubkov, A., Joson, E.S. and Lew, W.J., 2016. Factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012–2014. Emerging infectious diseases, 22(3), p.491.
https://wwwnc.cdc.gov/eid/article/22/3/15-1788_article

Tupasi, T., Garfin, A.M.C.G., Mangan, J.M., Orillaza-Chi, R., Naval, L.C., Balane, G.I., Basilio, R., Golubkov, A., Joson, E.S., Lew, W.J. and Lofranco, V., 2017. Multidrug-resistant tuberculosis patients' views of interventions to reduce treatment loss to follow-up. The International Journal of Tuberculosis and Lung Disease, 21(1), pp.23-31.
https://www.ingentaconnect.com/content/iuatld/ijtld/2017/00000021/00000001/art00007